Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer.

Carmen María Valencia SotoMaría Victoria Villacañas PalomaresAdela Garcia-Avello Fernández-CuetoSara Barbadillo VillanuevaVirginia Martínez CallejoMaría Ochagavía SufrateguiPedro Muñoz CachoMarta Valero Domínguez

Published in: European journal of hospital pharmacy : science and practice (2022)

Obtained data showed that patients with immune-related adverse events occurrence had significantly better overall response rate and longer progression-free survival and overall survival. This study highlights the role of immune-related adverse events as a predictor of survival in a real-life setting.

Keyphrases

free survival
risk assessment
electronic health record
big data
deep learning
smoking cessation